| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
Dengue virus (DENV) is the etiologic agent responsible for dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. The infections have emerged and continue to spread rapidly. Now no effective antiviral drugs exist to treat DENV infection and licensed vaccine is only available in a few countries. We show here that a compound cyclofenil (CF) has an inhibitory effect on growth of DENV in mammalian cells in vitro. CF exhibited antiviral activity to DENV in mammalian cells but not in mosquito cells, suggesting that CF may interact with a mammalian cell factor. Time-of-addition experiment indicates that CF may inhibit the late stage of the life-cycle of the DENV. We also succeeded in isolating CF-resistant virus, and several mutations with amino acid substitutions were identified in the mutant virus genome.
|
